An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S12, 2019. DOI: 10.25251/skin.3.supp.12. Disponível em: https://skin.dermsquared.com/skin/article/view/739. Acesso em: 19 apr. 2025.